跳至主要内容
临床试验/NL-OMON50462
NL-OMON50462已完成不适用

ASSESSMENT OF THE PERFORMANCE OF THE SECOND GENERATION PILLCAM COLON CAPSULE (PCCE 2) IN CROHN*S DISEASE, BEFORE AND AFTER TREATMENT WITH ANTI-TNF AGENTS OR VEDOLIZUMAB : SENSITIVITY TO CHANGE STUDY - STOC study

Academisch Medisch Centrum0 个研究点目标入组 27 人开始时间: 待定最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
入组人数
27

研究概览

简要总结

暂无简介。

研究设计

研究类型
Observational

入排标准

年龄范围
18 至 99(—)

入选标准

  • Active ileocolonic Crohn's disease with CDAI > 150
  • Elevated faecal calprotectin >250 ug/g and /or increased CRP levels(>5mg/l)
  • and/ or endoscopy showing ulcerations <3 months prior to screening without any
  • change in treatment, regardless of biomarkers.
  • Abdominal imaging clinically indicated in order to determine disease activity
  • before embarking on anti-TNF or vedolizumab treatment

排除标准

  • Any contraindication for colon capsule examination including swallowing
  • disorders, severe congestive heart failure, renal insufficiency or co-morbities
  • contraindicating these procedures.
  • More than 1 bowel resection for CD
  • Previous subtotal or total colectomy
  • Active (draining) fistulas
  • Known small bowel strictures
  • Short bowel syndrome or stoma
  • High suspicion of small bowel strictures.
  • Pacemaker or ICD

研究者

相似试验